期刊文献+

LINC01667在肝细胞癌进程中的效应作用及可能的分子机制研究

原文传递
导出
摘要 目的:探究LINC01667在肝细胞癌(Hepatocellular Carcinoma,HCC)进程中的效应作用及可能的分子机制。方法:基于TCGA数据库及本地队列,明确LINC01667在HCC患者中的表达差异,应用ROC曲线评估其诊断效能;transwell实验观测LINC01667对HCC迁移、侵袭恶性生物学行为的影响;裸鼠荷瘤实验观测过表达的LINC01667对体内HCC成瘤的影响;Westernblot检测HCC相关信号通路关键分子的表达变化以探究其影响HCC进程可能的分子机制。结果:LINC01667在HCC癌组织中表达显著上调(P<0.05),对HCC具有较好的诊断效能。体外实验表明,敲低LINC01667后HepG2细胞的迁移(P<0.01)和侵袭能力(P<0.05)被显著抑制;同时,体内实验表明,过表达的LINC01667具有促进HCC细胞系裸鼠荷瘤的能力。进一步的分子机制探究显示,LINC01667可能是通过激活MAPK和PI3K/AKT/mTOR信号通路发挥促癌作用。结论:LINC01667具有癌基因的生物学属性,其可通过激活MAPK和PI3K/AKT/mTOR信号通路促进HCC的恶性进程。
出处 《兵团医学》 2024年第2期1-5,共5页 Journal of BingTuan Medicine
基金 新疆维吾尔自治区自然科学基金面上项目(2022D01C245)
  • 相关文献

参考文献2

二级参考文献29

  • 1Bruix J, Sherman M, Llovet JM, et ol. Clinical management of he- patocellular carcinoma. Conclusions of the Bareelona-2000 EASL conference. European Association for the Study of the Liver[J]. J Hepatol, 2001, 35(3):421-430.
  • 2National Cancer Institute. Levels of evidence for adult and pedi- atric cancer treatment studies (PDQ?)[EB/0L]. [2012-07-12]. http:// www.cancer.gov/cancertopics/pdq/levels-evidence-aduh-treatment/ HealthProfessional/page 1.
  • 3European Association for the study of the liver; European Organi- sation for research and treatment of cancer. EASL-EORTC clini- cal practice guidelines: management of hepatoeellular carcinoma [J]. J Hepatol, 2012, 56(4):908-943.
  • 4Singal AG, Volk ML, Jensen D, eta/. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus[J ]. Clin Gastroenteml Hepatol, 2010, 8(3):280-288.
  • 5Lok AS, Seeff LB, Morgan TR, eta]. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related ad- vanced liver disease[J]. Gastroenterology, 2009, 136(1):138-148.
  • 6Marrero JA, Su GL, Wei W, et ol. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chro- nic liver disease in American patients[J]. Hepatology, 2003, 37(5): 1114-1121.
  • 7Bruix J, Sherman M. Management of hepatocellular carcinoma[J]. Hepatology, 2005, 42(5):1208-1236.
  • 8Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3):1020-1022.
  • 9International Consensus Group for Hepatocellular Neoplasia. Pa- thologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia[J]. He patology, 2009, 49(2):658-664.
  • 10Llovet JM, Chen Y, Wurmbach E, eta/. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcino- ma in HCV cirrhosis[J]. Gastroenterology, 2006, 131(6):1758-1767.

共引文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部